274 related articles for article (PubMed ID: 28131216)
21. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.
Shi B; Zhao M; Qiao L; Huang F; Zhou S; Wei Y; Wang J; Wang N
Mult Scler Relat Disord; 2021 Sep; 54():103143. PubMed ID: 34273608
[TBL] [Abstract][Full Text] [Related]
22. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
Gomez-Figueroa E; Noriega-Morales G; Casallas-Vanegas A; Zabala-Angeles I; Garcia-Estrada C; Neri D; Sarachaga AJ; Rivas-Alonso V; Corona-Vazquez T; Flores-Rivera J
Clin Neurol Neurosurg; 2020 Sep; 196():106007. PubMed ID: 32559706
[TBL] [Abstract][Full Text] [Related]
23. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
[TBL] [Abstract][Full Text] [Related]
24. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy.
Quan C; ZhangBao J; Lu J; Zhao C; Cai T; Wang B; Yu H; Qiao J; Lu C
J Neuroimmunol; 2015 May; 282():45-53. PubMed ID: 25903728
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y
BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862
[TBL] [Abstract][Full Text] [Related]
26. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
[TBL] [Abstract][Full Text] [Related]
27. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
[TBL] [Abstract][Full Text] [Related]
28. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
29. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Kim HJ
Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
[TBL] [Abstract][Full Text] [Related]
30. Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.
Lebrun C; Cohen M; Rosenthal-Allieri MA; Bresch S; Benzaken S; Marignier R; Seitz-Polski B; Ticchioni M
Neurol Ther; 2018 Dec; 7(2):373-383. PubMed ID: 29881979
[TBL] [Abstract][Full Text] [Related]
31. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
Ringelstein M; Harmel J; Distelmaier F; Ingwersen J; Menge T; Hellwig K; Kieseier B; Mayatepek E; Hartung HP; Kuempfel T; Aktas O
Mult Scler; 2013 Oct; 19(11):1544-7. PubMed ID: 23886825
[TBL] [Abstract][Full Text] [Related]
32. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
[TBL] [Abstract][Full Text] [Related]
33. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
Radaelli M; Moiola L; Sangalli F; Esposito F; Barcella V; Ferrè L; Rodegher M; Colombo B; Fazio R; Martinelli V; Comi G
Mult Scler; 2016 Apr; 22(4):511-9. PubMed ID: 26199350
[TBL] [Abstract][Full Text] [Related]
34. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
Ciron J; Audoin B; Bourre B; Brassat D; Durand-Dubief F; Laplaud D; Maillart E; Papeix C; Vukusic S; Zephir H; Marignier R; Collongues N;
Rev Neurol (Paris); 2018 Apr; 174(4):255-264. PubMed ID: 29606320
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.
Durozard P; Rico A; Boutiere C; Maarouf A; Lacroix R; Cointe S; Fritz S; Brunet C; Pelletier J; Marignier R; Audoin B
Ann Neurol; 2020 Feb; 87(2):256-266. PubMed ID: 31725931
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
[TBL] [Abstract][Full Text] [Related]
38. Individualized rituximab treatment for neuromyelitis Optica spectrum disorders.
McKeon A; Pittock S
JAMA Neurol; 2013 Sep; 70(9):1103-4. PubMed ID: 23896992
[No Abstract] [Full Text] [Related]
39. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
Greenberg BM; Graves D; Remington G; Hardeman P; Mann M; Karandikar N; Stuve O; Monson N; Frohman E
Mult Scler; 2012 Jul; 18(7):1022-6. PubMed ID: 22261118
[TBL] [Abstract][Full Text] [Related]
40. [Trial of rituximab in three patients with neuromyelitis optica].
Imamura H; Tanaka M; Kitagawa N; Tahara M; Oono M; Tanaka K; Konishi T
Rinsho Shinkeigaku; 2009 Aug; 49(8):457-62. PubMed ID: 19827593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
